Operational Ramp-Up of the Saitama Plant and Mexico Second Plant
First written in FY2017-Q1. 15 of 35 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「While the burden of front-loaded investment in new plants had increased and become a major factor behind the recent sluggish performance, the earnings structure improved in the fiscal year ending March 2026, including the Indonesia and India plants achieving profitability for the first time.」
Specific results in monetizing the new plants were reported, with the Indonesia and India plants achieving profitability for the first time. - FY2026-H1AdvancedAnnual report
「Progress at the Mexico Plant and continued expansion in the medical sector drove sales up 18.3% year on year to ¥3,016 million. The segment posted a profit of ¥327 million, compared with a loss of ¥23 million in the same period of the previous year.」
Progress at the Mexico Plant enabled the Americas segment to turn from a loss in the same period of the previous year to a profit of ¥327 million. Specific progress in monetizing the new plants continues to be reported. - FY2025AdvancedAnnual report
「In the fiscal year ending March 2025, the new plants made progress in improving their earnings structure, including sales reaching break-even.」
The disclosure reports specific progress toward monetization of the new plants, with sales reaching break-even. - FY2024AdvancedAnnual report
「We expect profitability to improve as the US plant, which returned to profitability in the fiscal year ending March 2024, continues to improve earnings in the fiscal year ending March 2025, the India Plant approaches profitability, and the decision to discontinue production functions at the Singapore Plant is expected to reduce the deficit. The Company aims to bring the Mexico Plant to profitability by the fiscal year ending March 2027 through Group-wide improvement efforts, including dispatching numerous experts.」
The disclosure reports the US plant's completed return to profitability, the outlook for the India Plant to become profitable, the discontinuation of production functions at the Singapore Plant, and the aim of bringing the Mexico Plant to profitability by the fiscal year ending March 2027. - FY2024-Q3AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 52.5% year on year to ¥3,182 million. Although the stronger Mexican peso increased fixed costs and other expenses, improved profitability at the US plant narrowed the segment loss to ¥328 million from ¥746 million in the same quarter of the previous year.」
The new plants in the Americas made progress in ramping up automotive and medical production, increasing sales by 52.5%. Improved profitability at the US plant also narrowed the segment loss from the previous year. - FY2024-Q2AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 58.0% year on year to ¥2,162 million. Although the stronger Mexican peso increased fixed costs and other expenses, improved profitability at the US plant narrowed the segment loss to ¥163 million from ¥546 million in the same quarter of the previous year.」
The US and Mexico plants made progress in ramping up automotive and medical production, resulting in a substantial increase in sales in the Americas segment. Improved profitability at the US plant narrowed the loss from ¥546 million in the same period of the previous year to ¥163 million. - FY2024-Q1AdvancedAnnual report
「Progress in ramping up automotive and medical production at the US and Mexico plants drove sales up 53.7% year on year to ¥1,007 million. Although the stronger Mexican peso increased fixed costs and other expenses, profitability improved at both plants, narrowing the segment loss to ¥84 million from ¥283 million in the same quarter of the previous year.」
The US and Mexico plants made progress in ramping up automotive and medical production and improving profitability, narrowing the Americas segment deficit from the previous year. - FY2023Outlook for the new plants to become profitableAnnual report
「We expect profitability to improve as the new plants, including those in the United States, India and the Czech Republic, approach profitability and the pass-through of higher costs into prices progresses.」
The disclosure has shifted from describing plant start-up and front-loaded investment burdens to an outlook that the new plants are approaching profitability and earnings improvement will progress. This is presented as the Company's outlook, not as a completed transition to profitability. - FY2023-Q3RestatedAnnual report
「Although operations at the new Tennessee Plant were delayed, the weaker yen helped drive sales up 4.3% year on year to ¥2,087 million.」
The delay in operations at the new Tennessee Plant continues to be reported. No new milestone involving completion or full-scale operations is indicated. - FY2023-Q2RestatedAnnual report
「Although operations at the new Tennessee Plant were delayed, progress in ramping up production at the Mexico Plant and the weaker yen drove sales up slightly year on year to ¥1,368 million. The segment loss was ¥546 million, compared with a loss of ¥340 million in the same quarter of the previous year, due in part to the delay at the new Tennessee Plant and higher material costs.」
Progress in ramping up production at the Mexico Plant and the delay at the new Tennessee Plant, both reported in the previous quarter, continue to be noted. No new milestone involving completion or full-scale operations is indicated. - FY2023-Q1Progress at the Mexico Plant, but delays at the new Tennessee PlantAnnual report
「Although operations at the new Tennessee Plant were delayed, progress in ramping up production at the Mexico Plant drove sales up 9.7% year on year to ¥655 million. The segment loss was ¥283 million, compared with a loss of ¥222 million in the same quarter of the previous year, due in part to the delay at the new Tennessee Plant and higher raw material costs.」
Progress in ramping up production at the Mexico Plant was reported, while operations at the new Tennessee Plant were delayed, contributing to the loss in the Americas segment. - FY2022RestatedAnnual report
「In the fiscal year ending March 2022, efforts to bring the new plants to break-even progressed, but operating restrictions due to the spread of COVID-19, production adjustments by customers caused by the semiconductor shortage, and sharply higher crude oil and raw material costs placed pressure on profitability, resulting in difficult results.」
Progress was noted in efforts to bring the new plants to break-even, but no specific milestone, such as completion of the plants' transition to profitability, was reported. - FY2022-Q3RestatedAnnual report
「The recovery in automotive and medical demand drove sales up 29.4% year on year to ¥2,002 million, but the segment loss was ¥467 million, compared with a loss of ¥262 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
Project start-up costs continue to be incurred at the Mexico Plant. Expenses related to relocating the US plant are also noted, but no milestone involving completion of start-up or full-scale operations is indicated. - FY2022-Q2RestatedAnnual report
「The recovery in automotive and medical demand drove sales up 48.5% year on year to ¥1,362 million, but the segment loss was ¥340 million, compared with a loss of ¥163 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
Project start-up costs continue to be incurred at the Mexico Plant, and no new milestone, such as full-scale operations or completion of start-up, is reported. - FY2022-Q1RestatedAnnual report
「The recovery in automotive and medical demand drove sales up 76.7% year on year to ¥597 million, but the segment loss was ¥222 million, compared with a loss of ¥151 million in the same quarter of the previous year, due to expenses associated with relocating the US plant and project start-up costs at the Mexico Plant.」
Project start-up costs continue to be incurred at the Mexico Plant. No new milestone involving completion or full-scale operations is reported. - FY2021AdvancedAnnual report
「In the fiscal year ending March 2021, results deteriorated sharply in the first half due to plant shutdowns and lower demand caused by COVID-19, in addition to those burdens. In the second half, the recovery in demand and the acceleration of mass production at the new plants reduced the start-up deficit, marking a shift toward earnings recovery.」
The disclosure states that the start-up deficit at the new plants narrowed as demand recovered and mass production ramped up in the second half, marking a shift toward earnings recovery. - FY2021-Q3WorsenedAnnual report
「In addition to a particularly sharp decline in automotive demand, the Mexico Plant was closed for approximately 2 months at the direction of the Mexican government. As a result, sales fell 17.7% year on year to ¥1,547 million, and the segment loss was ¥262 million, compared with a loss of ¥220 million in the same quarter of the previous year.」
The approximately 2-month closure of the Mexico Plant continued, and the Americas segment loss widened from ¥220 million in the same period of the previous year to ¥262 million. - FY2021-Q1WorsenedAnnual report
「In addition to a particularly sharp decline in automotive demand, the Mexico Plant was closed for approximately 2 months at the direction of the Mexican government. As a result, sales fell 50.2% year on year to ¥338 million, and the segment loss was ¥151 million, compared with a loss of ¥88 million in the same quarter of the previous year.」
The Mexico Plant start-up and monetization thread notes a closure of approximately 2 months at the direction of the government, which contributed to the widening loss in the Americas segment. - FY2020AdvancedAnnual report
「In the fiscal year ending March 2020, mass production of several new models began at the new plants, and the deficit caused by the front-loaded investment burden narrowed, marking a shift toward improved profitability. In the fiscal year ending March 2021, progress toward break-even at the new plants is expected to stall temporarily due to the impact of COVID-19.」
The start of mass production of new models at the new plants and the resulting reduction in the deficit caused by the front-loaded investment burden were reported as specific progress. However, progress toward break-even in the fiscal year ending March 2021 was expected to stall due to COVID-19. - FY2020-Q3RestatedAnnual report
「Although sales to the housing equipment and infrastructure sectors declined, expansion in the medical sector and other factors drove sales up 3.3% year on year to ¥1,880 million. The segment loss was ¥220 million, compared with a loss of ¥264 million in the same quarter of the previous year, as the deficit narrowed following the partial start-up of the Mexico Plant's automotive production line.」
The partial operation of the Mexico Plant's automotive production line and the resulting narrowing of the deficit continue to be reported. Completion of the entire plant or progress to a new operating stage is not indicated. - FY2020-Q2RestatedAnnual report
「Sales fell 2.2% year on year to ¥1,179 million due to sluggish automotive demand and the impact of foreign exchange. The segment loss was ¥132 million, compared with a loss of ¥205 million in the same quarter of the previous year, as the deficit narrowed following the partial start-up of the Mexico Plant's automotive production line.」
The partial operation of the Mexico Plant's automotive production line continues to be reported. No new operating stage or completion milestone is indicated. - FY2020-Q1AdvancedAnnual report
「The start of full-scale operations on part of the Mexico Plant's production line, together with strong performance in the medical sector and other factors, drove sales up 10.5% year on year to ¥678 million.」
Specific progress at the Mexico Plant was reported for the first time, with part of the production line entering full-scale operations. The Americas segment continued to report a loss due to higher start-up costs. - FY2019-Q3WorsenedAnnual report
「Strong performance in the medical sector and other factors drove sales up 10.7% year on year to ¥1,821 million, but the segment loss was ¥264 million, compared with a loss of ¥261 million in the same quarter of the previous year, due in part to higher Mexico Plant start-up costs and sharply higher material costs.」
Higher Mexico Plant start-up costs caused the Americas segment loss to widen year on year. - FY2019-Q2WorsenedAnnual report
「Strong performance in the medical sector and other factors drove sales up 6.4% year on year to ¥1,206 million, but the segment loss was ¥205 million, compared with a loss of ¥128 million in the same quarter of the previous year, due in part to higher Mexico Plant start-up costs and sharply higher material costs.」
Higher Mexico Plant start-up costs caused the Americas segment loss to widen from ¥128 million in the same period of the previous year to ¥205 million. - FY2019-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 23 July 2018, the Company resolved to expand the Saitama Plant, its automotive parts plant, as follows. Although the expansion had been planned from the outset, the Company decided to bring forward the start of construction because new orders were higher than expected and it became necessary to secure additional production space early. Planned investment: approximately ¥1 billion (land, buildings and equipment) Planned completion: around June 2019」
The Board of Directors resolved to expand the Saitama Plant, with construction scheduled to begin earlier than originally planned. The investment of approximately ¥1 billion and expected completion around June 2019 were specified. The expansion was disclosed as a significant subsequent event. - FY2018RestatedAnnual report
「Since announcing its medium-term management plan in February 2015, the Group has made proactive investments, including the incorporation of Funabashi Denshi Co., Ltd., the opening of the Saitama Plant and Mexico Plant, the acquisition of the business of Electronic Stamping Corporation in the United States, and the conversion of PT.Yamakou Indonesia in Indonesia (now PT.Advanex Precision Indonesia) into a wholly owned subsidiary. However, the new sites have taken time to reach break-even, placing pressure on overall profitability, and the Group's results for the fiscal year under review were therefore difficult.」
The full-year disclosure explicitly states that investment in new sites, including Saitama and Mexico, and the time required to reach break-even have placed pressure on profitability. The outlook for the new plants to become profitable is also provided, but no completed result is indicated. - FY2018-Q3RestatedAnnual report
「Strong performance in the automotive sector and other factors drove sales up 16.3% year on year to ¥1,645 million, but the segment loss was ¥261 million, compared with a loss of ¥96 million in the same quarter of the previous year, due in part to higher fixed costs from front-loaded investment at the Mexico Plant. *The plant in Querétaro, Mexico, opened in 2016」
The fixed-cost burden associated with front-loaded investment at the Mexico Plant since its opening in 2016 continues to be noted. No new milestone, such as plant completion or full-scale operations, is indicated. - FY2018-Q2RestatedAnnual report
「Although fixed costs increased due to capital investment at the Saitama Plant and other factors, strong performance in the automotive sector led to sales of ¥3,852 million, up 2.8% year on year, and a segment loss of ¥63 million, compared with a loss of ¥296 million in the same quarter of the previous year.」
The fixed-cost burden associated with capital investment at the Saitama Plant continues. Fixed-cost increases at the second plants in Mexico and the United States are also noted for the Americas, but no new milestone, such as plant completion or full-scale operations, is indicated. - FY2018-Q1RestatedAnnual report
「Although fixed costs increased due to capital investment at the Saitama Plant and other factors, strong performance in the automotive sector led to sales of ¥1,915 million, up 4.1% year on year, and a segment loss of ¥42 million, compared with a loss of ¥166 million in the same quarter of the previous year.」
The fixed-cost burden associated with capital investment at the Saitama Plant continues. Fixed-cost increases at the second plants in Mexico and the United States are also noted for the Americas, but no new milestone, such as completion or full-scale operations, is indicated. - FY2017RestatedAnnual report
「Although the automotive business remained strong, sales to the office automation equipment sector declined, and fixed costs increased due to the ramp-up of the Saitama Plant. As a result, sales decreased 0.1% year on year to ¥7,531 million, and the segment recorded a loss of ¥572 million.」
The fixed-cost burden associated with the ramp-up of the Saitama Plant continued for the full fiscal year. Plans were also presented for the Saitama Plant to begin full-scale operations, an expansion in Heisei 31, and the Mexico Second Plant to begin full-scale operations, but the completion or full-scale operation of these facilities is not stated as having been achieved. - FY2017-Q3RestatedAnnual report
「Although the automotive business remained strong, sales to the OA equipment sector declined, and fixed costs increased due to the ramp-up of the Saitama Plant. As a result, sales decreased 1.8% year on year to ¥5,614 million, and the segment recorded a loss of ¥441 million. Sales also declined due to the impact of the stronger yen and decreases in the automotive and housing equipment businesses, while fixed costs increased due to the ramp-up of the Mexico Second Plant. Accordingly, sales decreased 11.9% year on year to ¥1,414 million, and the segment recorded a loss of ¥96 million.」
The ramp-up of the Saitama Plant and Mexico Second Plant, along with the fixed-cost burden, continues to be cited. No new achievement of the completion or operating stage is mentioned. - FY2017-Q2RestatedAnnual report
「Although the automotive business remained strong, sales to the office automation equipment sector declined, and fixed costs increased due to the ramp-up of the Saitama Plant. As a result, sales decreased 4.8% year on year to ¥3,747 million, and the segment recorded a loss of ¥296 million. Sales also declined due to the impact of the stronger yen and decreases in the automotive and housing equipment businesses, while fixed costs increased due to the ramp-up of the Mexico Second Plant. Accordingly, sales decreased 15.6% year on year to ¥925 million, and the segment recorded a loss of ¥53 million.」
The ramp-up of the Saitama Plant and Mexico Second Plant, along with the associated fixed-cost burden, continues to be cited. No new achievement of the completion or operating stage is mentioned. - FY2017-Q1First statedAnnual report
「Although the automotive business remained strong, sales to the office automation equipment sector declined, and fixed costs increased due to the ramp-up of the Saitama Plant, which began operations in January 2016. As a result, sales decreased 6.9% year on year to ¥1,839 million, and the segment recorded a loss of ¥166 million.」
The disclosure states that the Saitama Plant began operations in January 2016 and that the Mexico Second Plant is also in the ramp-up phase. The increase in fixed costs associated with the ramp-up is also cited as a factor behind the loss in the current quarter.